The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2016

Filed:

Mar. 24, 2014
Applicants:

Development Center for Biotechnology, New Taipei, TW;

Academia Sinica, Taipei, TW;

Chang Gung Memorial Hospital, Taoyuan County, TW;

Inventors:

Alice L. Yu, New Taipei, TW;

John Yu, New Taipei, TW;

Ya-Hui Wang, New Taipei, TW;

Chuan-Lung Hsu, New Taipei, TW;

Yi-Chang Chen, New Taipei, TW;

Ying-Yung Lok, New Taipei, TW;

Assignees:

Development Center for Biotechnology, New Taipei, TW;

Academia Sinica, Taipei, TW;

Chang Gung Memorial Hospital, Taoyuan County, TW;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); C12Q 1/68 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3015 (2013.01); A61K 39/39558 (2013.01); C07K 16/30 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57496 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01); C12Q 2600/158 (2013.01);
Abstract

A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.


Find Patent Forward Citations

Loading…